– Esteemed Harvard Medical School Professor Emeritus and HHMI Investigator, Dr. David Clapham, brings world class expertise on ciliary ion channel biology –
CAMBRIDGE, MA – March 2, 2022 – Caraway Therapeutics today announced the appointment of David Clapham, MD, PhD, to the company’s Scientific Advisory Board (SAB). Dr. Clapham is one of the world’s foremost experts in ion channel biology and joins Caraway to advise the Company on its research and development programs.
“I am delighted to welcome Dr. Clapham to Caraway as a scientific advisor,” said Martin D. Williams, Chief Executive Officer at Caraway Therapeutics. “David has decades of expertise interrogating ion channel function and their impact on downstream cell signaling. His lab is a world-leader in the characterization of ciliary ion channels involved in rare genetic diseases, such as nephronophthisis (NPHP), Bardet-Biedl syndrome (BBS), and polycystic kidney disease (PKD). The combined cutting-edge expertise and wisdom David provides will be a key asset for Caraway as we continue to advance our programs.”
David Clapham, MD, PhD is a renowned ion channel biologist whose research focuses on understanding the impact of ion channels on cell signaling pathways and cell physiology. Dr. Clapham is the Aldo R. Castañeda Professor of Cardiovascular Research and professor emeritus of neurobiology at Harvard Medical School. He currently maintains a lab at the Howard Hughes Medical Institute (HHMI) Janelia Research Campus and previously served as HHMI vice president and chief scientific officer. Dr. Clapham was also elected to the National Academy of Sciences in 2006 and the National Academy of Medicine in 2021. He earned his MD and PhD degrees at Emory University School of Medicine. During his residency in Internal Medicine at Brigham and Women’s Hospital, he was a Fulbright fellow with Nobel Prize winner Erwin Neher at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany.
Dr. Clapham joins Caraway’s experienced, collaborative, and dedicated Scientific Advisory Board team comprised of tenured biologists and biotech leaders.
About Caraway Therapeutics
Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating lysosomal function. Caraway is utilizing its unique product engine to develop proprietary insights into lysosomal function and small molecule ion channel modulation and advance a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.
Caraway is based in Cambridge, MA. For more information, please visit www.carawaytx.com.
CONTACTS
MacDougall
Nick Chang or Kari Watson
(781) 235-3060
nchang@macdougall.bio or kwatson@macdougall.bio
